| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4003039 | American Journal of Ophthalmology | 2012 | 8 Pages |
Abstract
Intravitreal bevacizumab is generally well tolerated and improves BCVA in eyes with subfoveal idiopathic CNV over a period of 12 months. Large, randomized, controlled, long-term clinical trials are required to further evaluate the efficacy and optimal strategy of this treatment modality.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Han Zhang, Zhe-Li Liu, Peng Sun, Feng Gu,